S'abonner

The risk of venous thromboembolism in surgically treated hip fracture: A retrospective cohort study of 5184 patients - 03/02/22

Doi : 10.1016/j.otsr.2021.103142 
Philippe Beauchamp-Chalifour a, c, Étienne L. Belzile a, b, c, Reinemary Michael c, Valérie Langevin c, Noémie Gaudreau c, Nicolas Normandeau c, Luc Bédard a, b, c, Stéphane Pelet a, b, c,
a Division of Orthopaedic Surgery, Department of Surgery, Faculty of Medicine, Laval University, Quebec, QC, Canada 
b Department of Orthopedic Surgery, CHU de Québec, Hôpital Enfant-Jésus, 18e, rue, Québec, 1401 Québec, Canada 
c Centre de recherche FRQS, CHU de Québec, Hôpital Enfant-Jésus, 18e, rue, Québec, 1401 Québec, Canada 

Corresponding author.

Bienvenue sur EM-consulte, la référence des professionnels de santé.
Article gratuit.

Connectez-vous pour en bénéficier!

Abstract

Introduction

Elderly patients undergoing surgery for a hip fracture are at risk of venous thromboembolism (VTE). The known risk of VTE is low due to thromboprophylaxis (1.8–2.5% at three months). Most previous studies have ignored the high mortality in that population when calculating the risk of VTE. Hip fracture treatment has also evolved over the last decade. The real risk of VTE today is unknown. We asked what was the risk of symptomatic VTE following surgery for a hip fracture in an elderly population. We also asked what kind of bleeding events were associated with thromboprophylaxis.

Hypothesis

The risk of VTE will be lower than previously described due to modern postoperative care.

Patients and methods

Retrospective cohort study of all patients65-years-old undergoing surgery for a hip fracture in two Canadian academic centers, between January 1, 2008, and January 1, 2019. Symptomatic VTE (pulmonary embolism or deep venous thrombosis) confirmed by imagery were assessed. The follow-up was fixed at 3 months. The cumulated risks of VTE and bleeding events were calculated using the Kaplan–Meier estimator and a logistic regression model was used to determine risk factors.

Results

The cohort included 5184 patients. The mean age was 83±8 years old and 76% of patients were female. In total, 98.8% of this cohort received postoperative thromboprophylaxis. Low-molecular-weight heparin was given for 35 days in 87% of this cohort. The risk of venous thromboembolism was 4.7±0.5% at 3 months (n=144). Chronic obstructive pulmonary disease (odds ratio 1.6 [1.0–2.4]) and the use of warfarin as extended thromboprophylaxis (odds ratio 2.1 [1.3–3.6]) were associated with venous thromboembolism. The risk of bleeding was 5.9% (n=179) at 3 months. In total, 78% (n=141) of bleeding events were hematomas, of which only 12% (n=16) needed reoperation. The use of direct oral anticoagulant was associated with an increased risk of bleeding events (odds ratio, 2.8 [1.5–5.0]). Mortality at 3 months was 8.4%.

Discussion

The risk of venous thromboembolism is higher than expected in a population treated for this condition (4.7% vs. 1.8–2.5% at 3 months as previously described). Bleeding events were mostly hematomas and few needed reoperations for wound complication. Future research should focus on the management of thromboprophylaxis in that population.

Level of evidence

III; retrospective cohort study.

Le texte complet de cet article est disponible en PDF.

Keywords : Hip fractures, Venous thromboembolism, Hemorrhage, Heparin, Low-molecular-weight


Plan


© 2021  Elsevier Masson SAS. Tous droits réservés.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 108 - N° 1

Article 103142- février 2022 Retour au numéro
Article précédent Article précédent
  • Effects of carbazochrome sodium sulfonate combined with tranexamic acid on hemostasis and inflammation during perioperative period of total hip arthroplasty: A randomized controlled trial
  • Yue Luo, Yeersheng Releken, Dan Yang, Yong Yue, Zi Liu, Pengde Kang
| Article suivant Article suivant
  • Return to work after primary total hip or knee arthroplasty. First French study. Retrospective study of 241 cases
  • Mickael Mangin, Florent Galliot, Fayçal Houfani, Cédric Baumann, Didier Mainard

Bienvenue sur EM-consulte, la référence des professionnels de santé.

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.


Tout le contenu de ce site: Copyright © 2025 Elsevier, ses concédants de licence et ses contributeurs. Tout les droits sont réservés, y compris ceux relatifs à l'exploration de textes et de données, a la formation en IA et aux technologies similaires. Pour tout contenu en libre accès, les conditions de licence Creative Commons s'appliquent.